ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
F/m Emerald Life Sciences Innovation ETF
45.33
0.0000
成交量：
256
成交額：
1.17萬
市值：
1.28億
市盈率：
- -
高：
45.33
開：
45.33
低：
45.33
收：
45.33
52周最高：
48.78
52周最低：
27.68
股本：
281.70萬
流通股本：
281.70萬
量比：
0.14
換手率：
0.01%
股息：
- -
股息率：
- -
淨資產收益率：
--
總資產收益率：
--
市淨率：
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。
智通财经
·
09/12
Spyre Therapeutics旗下Spy003療法在第12周實現20%臨床緩解率及30%內鏡改善率
美股速递
·
09/08
Guardant Health重磅里程碑：Guardant360® Cdx獲FDA批准，成為阿斯利康Ectamah™（Camizestrant）晚期乳腺癌伴隨診斷
美股速递
·
09/05
Cogent Biosciences將向Hovione採購Bezuclastinib產品最低比例
美股速递
·
09/03
Cogent Biosciences協議生效：為期五年，自動續約兩年——SEC文件披露
美股速递
·
09/03
美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極
格隆汇
·
09/01
藥聞 | 英硅智能上市後首份半年報扭虧 創新藥研發加速擁抱AI
新华财经
·
08/31
聯環藥業上半年扭虧為盈 集採續採與創新藥研發協同推進
证券日报
·
08/30
博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑
蓝鲸财经
·
08/27
BUZZ——美國股市動態-Semtech、唐納森、Meta
路透中文
·
08/26
Spyre股價下跌，因關節炎藥物未達研發目標
路透中文
·
08/26
Spyre Therapeutics盤前股價重挫12.4% 實驗性藥物未達類風濕關節炎單藥治療開發門檻
美股速递
·
08/26
Spyre Therapeutics公司——療效幅度未達公司預設目標，類風濕關節炎候選藥物SPY072單藥療法開發優先級或將調整
美股速递
·
08/26
Spyre Therapeutics公司：Spy072聯合Il17-a/F治療化膿性汗腺炎（HS）預計於2027年末或2028年初啓動
美股速递
·
08/26
Spyre Therapeutics——Spy072在多項終點指標上較安慰劑展現統計學顯著優勢
美股速递
·
08/26
Spyre Therapeutics公布Spy072 Skyway二期試驗類風濕關節炎亞研究頂線結果
美股速递
·
08/26
美國法院在DNA測序專利糾紛案中裁定Guardant公司支付2.45億美元
路透中文
·
08/24
Twinstrand：法院判決公司及Uw獲賠逾2.452億美元，涵蓋截至2026年5月31日的侵權損害賠償、應計特許權使用費及利息
美股速递
·
08/24
Twinstrand勝訴：法院維持2023年故意侵權判決，並裁定Guardant Health 11項產品與服務須支付6%特許權使用費
美股速递
·
08/24
Twinstrand案判決：Guardant Health須按季度向公司及承銷商彙報11款產品與服務的全美銷售明細
美股速递
·
08/24
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/LFSC/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":45.3275,"timestamp":1789408636282,"preClose":45.3275,"halted":0,"volume":256,"delay":0,"changeRate":0,"floatShares":2817035,"shares":2817035,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"09-14 14:08:41 EDT","open":45.3275,"high":45.3275,"low":45.3275,"amount":11674.67392,"amplitude":0,"askPrice":46.13,"askSize":200,"bidPrice":45.96,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789416000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":45.3275,"sharesOutstanding":2657035,"nav":45.4,"aum":125169389,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":46.02,"preClose":45.3275,"latestTime":"19:30 EDT","volume":10,"amount":452.9875,"timestamp":1789169406017,"change":0.6925,"changeRate":0.015278,"amplitude":0},"volumeRatio":0.143461},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2817035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.143461,"shares":2817035,"dividePrice":0,"high":45.3275,"amplitude":0,"preClose":45.3275,"low":45.3275,"week52Low":27.6794,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":45.3275,"committee":-0.333333,"eps":0,"divideRate":0,"volume":256,"delay":0,"ttmEps":0,"open":45.3275,"prevYearClose":36.6147,"prevWeekClose":45.3275,"prevMonthClose":45.79,"prevQuarterClose":45.2033,"fiveDayClose":46.1341,"twentyDayClose":47.0833,"sixtyDayClose":40.7444},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666571008","title":"阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PBPH","LU2322448791.USD","IEHS","HELX","GNOM","LU1992135399.USD","TMED","BIB","FBT","XPH","PPH","BK4588","LU2272731865.HKD","RXL","PBE","LU1992135472.HKD","CANC","SYNB","MEDI","BME","BBP","BBH","XBIX","RSPH","IE00B5TLWC47.USD","IDNA","IBB","BIOY","PJP","IBRN","MRNX","LU2272731600.USD","IEIH","FTXH","AZNH","IYH","LFSC","LU2322448957.HKD","BK4585","PSCH","SBIO","MRNY","WDNA","LU2473716301.USD","LU2272731782.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121233294","title":"Spyre Therapeutics旗下Spy003療法在第12周實現20%臨床緩解率及30%內鏡改善率","url":"https://stock-news.laohu8.com/highlight/detail?id=1121233294","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121233294?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:03","pubTimestamp":1788868991,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics日前宣布，其研发管线中的关键候选药物Spy003在临床试验中交出了令人瞩目的阶段性答卷。数据显示，在接受治疗满12周的时间节点上，该疗法成功促成了20%的患者达到临床缓解状态，与此同时，30%的受试者在内镜检查中观察到了显著的病情改善迹象。这一成果不仅彰显了Spy003在疾病修饰层面的潜在威力，也为公司后续的注册性临床推进注入了强劲信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116354483","title":"Guardant Health重磅里程碑：Guardant360® Cdx獲FDA批准，成為阿斯利康Ectamah™（Camizestrant）晚期乳腺癌伴隨診斷","url":"https://stock-news.laohu8.com/highlight/detail?id=1116354483","media":"美股速递","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116354483?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 06:11","pubTimestamp":1788559873,"startTime":"0","endTime":"0","summary":"Guardant Health今日宣布，其Guardant360 Cdx液体活检产品已获得美国食品药品监督管理局的里程碑式批准，正式成为阿斯利康新型内分泌疗法Ectamah在晚期乳腺癌治疗中的伴随诊断工具。Guardant Health管理层在声明中表示，这一里程碑不仅是对公司技术实力的权威认可，更是对癌症患者个体化治疗承诺的有力践行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNOM","LU0109394709.USD","BK4196","GH","LFSC","GDOC","LU0320765992.SGD","GNMX","FFOX","PTH","BK4585","LU0889565916.HKD","EKG","BK4551","BK4535","HELX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107575074","title":"Cogent Biosciences將向Hovione採購Bezuclastinib產品最低比例","url":"https://stock-news.laohu8.com/highlight/detail?id=1107575074","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107575074?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 04:14","pubTimestamp":1788380059,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc. 已通过SEC文件披露，计划向Hovione采购Bezuclastinib产品的指定最低比例份额。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","BK4505","BK4139","LFSC","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126702774","title":"Cogent Biosciences協議生效：為期五年，自動續約兩年——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1126702774","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126702774?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 04:13","pubTimestamp":1788379990,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc. 的某项协议已正式生效，其初始期限设定为五年。根据美国证券交易委员会（SEC）的备案文件，该协议条款中包含自动续约机制——每当五年期限届满，协议将自动延长两年。这一续约安排，为合作双方的长期关系提供了延续性预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COGT","LFSC","CANC","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664521258","title":"美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極","url":"https://stock-news.laohu8.com/highlight/detail?id=2664521258","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664521258?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 22:18","pubTimestamp":1788272338,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4007","BBP","MEDX","RSPH","IBB","GNOM","WDNA","IE00BFTCPJ56.SGD","MRNX","PBPH","PSCH","IBRN","IE00B4R5TH58.HKD","IYH","BK4588","SYNB","BIB","PPH","LU2322448957.HKD","RXL","IEHS","PBE","HELX","SBIO","AZNH","BK4585","IE0009355771.USD","LFSC","MRNY","LU2473716301.USD","IE0002141913.USD","NVS","BBH","FTXH","LU2272731600.USD","IE00BJT1NW94.SGD","XPH","MEDI","CANC","FBT","LU0211331839.USD","XBIX","BIOY","LU0070302665.USD","TMED","PJP","IEIH","IE00BJJMRZ35.SGD","IDNA","BME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663282078","title":"藥聞 | 英硅智能上市後首份半年報扭虧 創新藥研發加速擁抱AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2663282078","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663282078?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 15:35","pubTimestamp":1788161758,"startTime":"0","endTime":"0","summary":"新华财经上海8月31日电（记者杜康）作为AI制药领域代表性企业之一，英硅智能（03696.HK）日前发布2026年度中期业绩报告。上半年，公司实现总营收1.063亿美元，同比增长287.2%；净利润3554万美元，经调整净利润5123万美元，经营活动现金流转正。这是英硅智能上市后发布的首份半年报，公司也由此前的亏损转为盈利。从收入结构看，药物研发与管线开发仍是主要来源。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860072952.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860072952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CHAT","QTOC","BIOY","AGIX","GDOC","IPOS","LFSC","WRND","GSKH","APXH","BBP","BK4585","SBIO","IBB","XLVI","ARTY","AIPO","PBE","VTHR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044177","title":"聯環藥業上半年扭虧為盈 集採續採與創新藥研發協同推進","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044177","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663044177?lang=zh_tw&edition=fundamental","pubTime":"2026-08-30 21:12","pubTimestamp":1788095520,"startTime":"0","endTime":"0","summary":"业绩实现扭亏为盈经营基本面持续改善今年上半年，联环药业经营业绩实现明显改善。对此，联环药业正持续推进相关工作。值得注意的是，联环药业已经开始围绕创新药商业化进行营销体系布局。除LH-1801外，联环药业产品注册申报也取得阶段性进展。从核心产品稳定销售，到集采品种持续放量，再到创新药研发向上市申报环节推进，联环药业正在逐步形成多层次的业务增长支撑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WRND","GSKH","PBE","BK4588","LFSC","BBP","SBIO","BIOY","APXH","XLVI","BK4585","GDOC","IBB","BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662752987","title":"博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662752987","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662752987?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:57","pubTimestamp":1787813849,"startTime":"0","endTime":"0","summary":"然而，需警惕新药研发政策变化、项目执行延期及市场竞争加剧带来的风险，同时关注经营现金流与净利润背离的情况。后续需重点关注公司在手订单转化进度、临床前及临床研究服务的毛利率变化趋势，以及经营现金流的改善情况。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787797151251328663","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BBP","GDOC","XLVI","BK4585","BK0216","SBIO","159399","IBB","BK4588","GSKH","SPHQ","APXH","WRND","300404","LFSC","PBE","BIOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662571159","title":"BUZZ——美國股市動態-Semtech、唐納森、Meta","url":"https://stock-news.laohu8.com/highlight/detail?id=2662571159","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662571159?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 20:32","pubTimestamp":1787747524,"startTime":"0","endTime":"0","summary":"BUZZ——美国股市动态-Semtech、唐纳森、Meta工作区中用于查询单只股票行情的搜索字符串：STXBZ《今日展望》通讯：https://refini.tv/3LI4BU7《晨间新闻简报》：https://refini.tv/3dKUyB8路透8月26日-周三，美国股指期货基本持平，因投资者在人工智能龙头企业Nvidia(辉达/英伟达)公布财报以及可能影响利率预期的备受关注的通胀报告发布前保","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4S44N0Y5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0003U64NQ7.SGD","LU1244550494.USD","BK4543","ARTY","LU0433182093.SGD","LU2326559502.SGD","LU0689472784.USD","LU2272731865.HKD","LU2361044865.SGD","BBWI","BK4505","AGOX","LU0347712357.USD","LU2322448791.USD","LU2491050071.SGD","LU0170899867.USD","LU0149725797.USD","SNPE","CHPX","LU1917777945.USD","LU2473716301.USD","LU1127390331.HKD","LFGY","IE00B19Z9505.USD","SG9999014567.USD","IE00BMPRXQ63.HKD","LU1934455863.HKD","LU2286300806.USD","2NVD.UK","LU2065169927.USD","IGV","LU1093756168.USD","IE0009355771.USD","NVYY","LU1880398471.USD","TEK","LU1121112475.USD","HK0000304797.USD","LU0289739343.SGD","LU0957808578.USD","LU0082616367.USD","WISE","LU0175139822.USD","OGIG","LU2047632596.USD","CMAG","LU1066051498.USD","LU0203347892.USD","ADBU","LU0130103400.USD","LU2324357040.USD","SG9999002232.USD","IE00B19Z3B42.SGD","LU1035775433.USD","LU2756315664.SGD","ZM","IE00BD6J9T35.USD","LU0256863811.USD","LU0106261612.USD","CNEQ","LU1804176565.USD","BK4527","TRUP","LU0345769128.USD","LU0965509283.SGD","LU0198837287.USD","LU1267930490.SGD","LU0820561818.USD","LU0077335932.USD","LU0985320562.USD","BK4554","LU2249611893.SGD","SG9999014542.SGD","LU0310799852.SGD","LU1043141396.HKD","LU2237438978.USD","LU1037948541.HKD","LU1116320901.HKD","LU2125909247.SGD","LU1868836591.USD","LU0143551892.USD","LU1839511570.USD","LU1861559042.SGD","METU","07388","IXN","LU1564329628.SGD","LU2065171311.SGD","LU2125154778.USD","BK4587","LU1551013342.USD","LU1267930573.SGD","BK4548","LU0395794307.EUR","XLC","LU1057294990.SGD","HK0000532082.HKD","LU2458330169.SGD","LU0056508442.USD","LU1861127337.USD","ESUM","LU0320765489.SGD","LU0052756011.USD","LU0215105999.USD","LU0251131958.USD","LU2404859667.USD","LU0251132253.USD","LU0130518102.USD","IE00BJTD4V19.USD","LU2506952097.USD","PLTU","PLT","LU2095319765.USD","IE00BYQQ9H92.USD","LU2764263039.SGD","BK4567","LU2430703178.SGD","LU1815333072.USD","LU2506951875.HKD","LU1564329032.USD","IE00BJJMRX11.SGD","IE00BJTD4N35.SGD","LU1235294995.USD","LU0012050646.USD","LU1202635105.USD","LU0640476718.USD","ADBG","LU2458330243.SGD","LU2552382132.HKD","LU0057025933.USD","LU1366192091.USD","CHAT","LU2250418816.HKD","LU0985489474.SGD","NULC","LU1035773651.USD","LU2210149790.SGD","LU0426417589.USD","LU1242518931.SGD","LU1674673428.USD","LU2381873111.SGD","LU2125909593.SGD","LU1267930227.SGD","LU0979878070.USD","IE00B5949003.HKD","IE00BDCRKT87.USD","LU2746668461.USD","LU0553294199.USD","PLTI","LU2237443382.USD","PLTG","SGXZ23171101.USD","PLTW","LU1821325948.USD","IE0004091025.USD","LU0949170426.SGD","NVDQ","LU2357125470.USD","SHOC","LU0096364046.USD","LU0320765059.SGD","BK4550","LU2764262908.HKD","LU2097344431.USD","LU0174119429.USD","SOXQ","LU0109392836.USD","IE0000B7K699.USD","LU2265009873.SGD","LU1868837300.USD","LU2237443978.SGD","LU2237957902.USD","LU0006306889.USD","LU0912757837.SGD","IE000YTNTUN2.SGD","SGXZ99366536.SGD","BK4535","LU0642271901.SGD","BK4613","LU1244550221.USD","LU0211327993.USD","LU1868836757.USD","LU1699723380.USD","CLSE","LU2322448957.HKD","LU2461242641.AUD","SMETAmain","IE00B19Z8X17.USD","LU0552385451.USD","LU0784383803.USD","IE00B775SV38.USD","LU1316542783.SGD","IE00BN29S564.USD","LU1629891620.HKD","LU1201861165.SGD","HK0000306685.HKD","LU0029864427.USD","BK4614","LU2106854487.HKD","VGT","LU2092937148.SGD","HK0000914686.HKD","LU0353189763.USD","IE00B19Z8W00.USD","LU1144417596.USD","LU2756315318.SGD","LU2023251221.USD","SYRE","LU1145028129.USD","NVDL","LU2543165471.USD","LU2125909916.SGD","LU1291159041.SGD","BK4162","IE0034235303.USD","LU1400636491.USD","LU1691799644.USD","BK4598","LU1267930730.SGD","IE0002141913.USD","LU0265550946.USD","LU0208291251.USD","LU2360106780.USD","LTL","LU2210150020.SGD","NOW","LU1712237335.SGD","LU0238689110.USD","IE00B7KXQ091.USD","LU0130102774.USD","LU0310800965.SGD","LU1670710588.SGD","LU1988902786.USD","FBY","LU2750360641.GBP","LU2452424414.USD","PTIR","LU1400636657.SGD","PLTY","LU0444971666.USD","IE00BKVL7J92.USD","LU0466842654.USD","LU0094547139.USD","HK0000306701.USD","LU1571399168.USD","LU1645745479.HKD","LU0784384876.USD","LU1435385759.SGD","LU2168563687.JPY","SG9999001077.SGD","IE00BZ1G4Q59.USD","LU1496350171.SGD","LU1935043536.SGD","IE00B7SZLL34.SGD","SG9999017495.SGD","LU2168564222.USD","LU0980610538.SGD","IE00BFSS7M15.SGD","SGXZ81514606.USD","LU0162691827.USD","LU0511384066.AUD","LU1116320737.USD","NOWL","PLTZ","IE0034235188.USD","LU0054578231.USD","SG9999004303.SGD","LU0205194284.USD","SPLTRmain","LU0792757196.USD","LU0878866978.SGD","SGXZ51526630.SGD","LU0048584097.USD","LU0868494617.USD","LU2054465674.USD","NVD3.UK","IE000W1ABFV2.USD","LU0154236417.USD","SG9999014880.SGD","IE00B4R5TH58.HKD","FBX","LU2168564149.EUR","LU2361044949.HKD","LU0069063385.USD","LU0882574055.USD","LU0545039389.USD","LU0788109477.HKD","PLTR","IE00B3M56506.USD","VT","LU0266013472.USD","LU0820561909.HKD","LU2100268510.USD","LU2637965513.SGD","LU2237443895.HKD","LU0823417737.USD","RSPC","LU0823434583.USD","LU1951200564.SGD","LU0345770308.USD","LU2360107168.USD","LU2552382058.USD","LU2506952170.USD","LU0784385840.USD","LU2237957811.SGD","METV","LU0314104364.USD","LU0661504455.SGD","LU0130517989.USD","LU2097344357.USD","LU1732799900.SGD","BK4107","SNVDAmain","IE00BQXX3D17.EUR","BK4141","LU0109391861.USD","GUNZ","BK4529","LU1923623000.USD","LU2954938101.SGD","LU2148611432.USD","SG9999001176.USD","LU1868837136.USD","PLOO","SG9999015986.USD","BK4534","LU0107464264.USD","LU0274383776.USD","LU0128525929.USD","LU0823417653.USD","IE00BYXW3230.USD","SG9999018865.SGD","DIPS","LU2413666426.HKD","LU2357305700.SGD","LU0965509010.AUD","LU1923622291.USD","ROM","LU0724617625.USD","LU0889566641.SGD","LU1823568750.SGD","LU1914381329.SGD","LU2236285917.USD","LU0211331839.USD","FCOM","GB00B4QBRK32.GBP","IE00BKPKM429.USD","NVDO","LU0157215616.USD","LU1670711123.USD","LU1069344957.HKD","LU0225283273.USD","LU0957791311.USD","LU1721428933.USD","BK4608","LU1791710582.SGD","LU1979441026.SGD","LU2491050154.USD","USD","LU1989764664.SGD","LU1119994496.HKD","LU0122379950.USD","LU0124676726.USD","LU0426412945.USD","LU2471134879.HKD","METW","SG9999014906.USD","IE00BFTCPJ56.SGD","LU2089284900.SGD","LU2237443465.HKD","NVDG","LU2279689827.SGD","SG9999014914.USD","IE000SO60NU8.SGD","LU0417517546.SGD","LU2237443549.SGD","LU2746668974.SGD","BK4082","IE00BDRTCR15.USD","LU2764263203.CNY","HK0000320223.HKD","IE00B3S45H60.SGD","LU0726765562.USD","LU1868836914.USD","LU0690374615.EUR","NVDY","LU1852331112.SGD","LU0964807845.USD","LU2237443622.USD","SG9999013999.USD","SGXZ80539844.SGD","FBL","SG9999015952.SGD","BK4503","LU0942090050.USD","LU0070217475.USD","LU2860962120.EUR","BK4538","LU2168564495.EUR","CRM","LU0289961442.SGD","BK4549","LU0310800379.SGD","LU0528227936.USD","LU2087625088.SGD","CRMG","LU1861558580.USD","LU0203201768.USD","LU1720051017.SGD","IE00BWXC8680.SGD","GAMR","NVDD","LU0053666078.USD","LU0345768153.USD","LU0323239441.USD","LU2023250330.USD","BK4551","LU0494093205.USD","LU0683600562.USD","LU1074936037.SGD","LU1564329115.USD","LU0823434740.USD","LU1551013425.SGD","SG9999001424.SGD","LU1718418525.SGD","LU2294711713.HKD","BHVN","LU0823414551.USD","TTXU","LU2602419157.SGD","LU1732800096.USD","LU2125154935.USD","LU0719512351.SGD","LU1992135399.USD","LU1003077747.HKD","ANV","LU0477156797.USD","LU1496350502.SGD","GXPC","BK4581","NVDA","LU0823421416.USD","SHLD","IE0005OL40V9.USD","LU0689626769.HKD","LU2092627202.USD","PLTL","SG9999015978.USD","ADBE","BK4561","AIPI","LU2242650005.HKD","LU1244550577.SGD","LU1814569148.SGD","BK4097","LU1066051811.HKD","TYLG","LU2065171402.SGD","IE00B2B36J28.USD","LU1400636574.HKD","LU2462591277.SGD","LU2487616109.SGD","TRFK","LU0432979614.USD","LU0070302665.USD","LU2063271972.USD","LU1989764748.USD","BK4612","SMHX","LU0742534661.SGD","METQ","LU2505996509.AUD","LU0672654240.SGD","ESLG","LU0345768740.USD","LU1803068979.SGD","SG9999002224.SGD","IE0009356076.USD","LU1941712264.USD","LU2133065610.SGD","IE00BZ199S13.USD","LU0158827781.USD","LU0127658192.USD","LU0786609619.USD","LU2065170008.USD","XLK","LU2247934214.USD","LU1791710400.SGD","LU2087621335.USD","ABFL","LU0081259029.USD","IE000Q6AESB8.SGD","IE00BK4W5M84.HKD","LU1366333091.USD","IE00B19Z9P08.USD","HK0000304805.HKD","LU0096362180.USD","PLTD","LU1059921491.USD","IE00BMPRXR70.SGD","LU1046421795.USD","LU1989772840.SGD","LU1066051225.USD","LU1429558221.USD","LU0276348264.USD","LU1037948897.HKD","LU2361045086.USD","LU0950375773.USD","LU2506951792.HKD","LU2463028550.USD","BK4607","IE00BJT1NW94.SGD","LU0323591593.USD","LU2471134796.USD","IE00BK4W5L77.USD","LU0061475181.USD","LU0648000940.SGD","LU2112291526.USD","FTEC","LU0011850046.USD","IETC","LU2077746001.SGD","LU2244417387.USD","LU3102509885.SGD","LU0210528500.USD","LU1236620834.HKD","LU2999663052.SGD","LU0128525689.USD","LU1093756325.SGD","LU1043141123.HKD","LU2505996681.GBP","FAI","BK4579","LU0289960550.SGD","LU0323240290.USD","LU1061106388.HKD","LU1564329461.SGD","LU1670710661.SGD","SGXZ31699556.SGD","LU0476273544.USD","LU1242518857.USD","LU1674673691.USD","LU1935042215.USD","GB00BDT5M118.USD","LU0080751232.USD","LU2097829019.USD","LU2433249047.HKD","SG9999015945.SGD","LU0787776722.HKD","LU2272731600.USD","LU1023059063.AUD","LU1923622614.USD","IE00B4JS1V06.HKD","NVDU","SG9999000418.SGD","SG9999001176.SGD","LU2347655156.SGD","IE0004086264.USD","LU0889565833.HKD","LU1153585028.USD","SOXY","BK4585","LU0345774391.USD","EFIV","IE00BJLML261.HKD","NVII","LU1280957306.USD","BK4547","LU1880398554.USD","TTEQ","LU1989772923.USD","HK0000320264.USD","LU1935043023.USD","LU1941712348.USD","XDAT","LU0256863902.USD","IE00B5TLWC47.USD","LU0205193047.USD","LU0557290698.USD","IE00BKDWB100.SGD","LU0823421333.USD","CLOD","LU0061474960.USD","LU0823414478.USD","LU2360032135.SGD","HK0000819398.USD","LU0048573561.USD","LU0203202063.USD","SOCL","LU1935042488.USD","LU0738911758.USD","LU0079474960.USD","LU1489326972.SGD","LU2491049909.HKD","IE00BFXG0V08.USD","LU2242649171.HKD","NVD","LU2023250504.SGD","LU0994945656.USD","LU0308772762.SGD","THMR","LU2430703095.HKD","LU2211815571.USD","IE00BQXX3F31.USD","LU2471134523.USD","LU0265550359.USD","LU0210536198.USD","LU1778281490.HKD","VOX","LU2108987350.USD","IE0004445015.USD","LU2471134952.CNY","IE000KEQY171.SGD","LU0354030438.USD","NVIW.SI","IE00B1BXHZ80.USD","IE00B1XK9C88.USD","LU2125909759.SGD","LU1720051108.HKD","IE00B19Z9Z06.USD","LU2111349929.HKD","SG9999014898.SGD","IE00BZ9MQY76.HKD","LU0133085943.USD","LU0072462426.USD","IE00BHPRN162.USD","LU2083900584.USD","LU2750360997.AUD","LU2462157665.USD","LU0784385170.HKD","LU0158827948.USD","LU0795875086.SGD","LU1633808545.USD","IE00BFSS8Q28.SGD","BK4200","LU0708995401.HKD","LU0234572021.USD","NVDS","LU1084165304.USD","GB00B4LPDJ14.GBP","NVDX","BK4566","LU1861215975.USD","BK4507","LU2430703251.USD","IE0002270589.USD","LU1934455277.USD","BK4077","LU0472753341.HKD","LU1983260115.SGD","IE00B775H168.HKD","LU0820562030.AUD","LU2089985449.USD","IE0001KFT4U8.USD","LU2023250843.SGD","LU1066053197.SGD","LU0390134368.USD","LU0949170772.SGD","LU1323610961.USD","META","SMTG","LU1934455194.USD","LU0348723411.USD","LU2264538146.SGD","SG9999018857.SGD","LU0072461881.USD","BSX","LU1697837992.HKD","BK4588","LU0823416689.USD","BK4528","USXF","BK4161","LU2462591350.SGD","PLTA","LU2290526834.HKD","BK4023","LU0234570918.USD","LU0068578508.USD","LU0868494708.USD","LU1642822529.SGD","LU1064131342.USD","SG9999015341.SGD","IE0004445239.USD","SMTC","BK4525","LU1236620750.USD","LU1983299246.USD","LU1861220033.SGD","LU1670627923.USD","ILDR","LU2168564065.EUR","LU2089283258.USD","IE000F7OJYX1.SGD","LU0342679015.USD","LU2028103732.USD","LU2404859741.USD","NVC","LU1623119135.USD","LU2896262040.SGD","LFSC","IE000MB6IJN5.SGD","BK4524","LU2317271919.USD","BK4139","LU0345774631.USD","LU2362541513.USD","BK4504","SGXZ57979304.SGD","LU1974910355.USD","IE00B894F039.SGD","07788","LU0477156953.USD","BK4533","LU0354030511.USD","LU0353189680.USD","LU0187121727.USD","LU1201861249.SGD","NVDW","IE000WAW04H5.SGD","LU0345769631.USD","LU0861579265.USD","METG","LU0648001328.SGD","IE00B3SWFQ91.USD","BK4532","IE0009G5SDU7.USD","SOXX","NVD2.UK","IE00BQXX3C00.GBP","LU2347655073.USD","LU0097036916.USD","LU2420271590.USD","LU0203345920.USD","IE00B4YYXB79.USD","LU2272731782.SGD","LU2592432038.USD","LU1815336760.USD","SG9999014575.USD","LU2456880835.USD","INTU","LU1951198990.SGD","LU0211328371.USD","TRUC","METD","SG9999015358.SGD","IE0034235295.USD","NVDS.UK","LU1261432733.SGD","BK4592","LU0106261372.USD","LU0690374961.EUR","LU0708994859.HKD","LU2271345857.HKD","LU0444973449.USD","LU2362541273.HKD","HK0000914660.USD","LU1670628061.USD","LU0943347566.SGD","BK4605","LU1301847155.USD","LU1548497426.USD","LU2362540622.SGD","SPTE","LU0965509101.SGD","LU0345770993.USD","LU1935042991.SGD","SG9999014559.SGD","LU0267386448.USD","LU1989771016.USD","NOWX","LU2417539215.USD","EYES","LU2403377893.USD","IE00BMPRXN33.USD","LU0882574139.USD","FBYY","LU2394011477.USD","AIFD","LU0316494557.USD","LU2413666699.HKD","LU2506951958.HKD","SNVD.UK","LU0795875169.SGD","LU1232071149.USD","LU1069347547.HKD","LU2213496289.HKD","LU1267930813.SGD","LU1992135472.HKD","SMH","LU2191332357.HKD","IE000ITXATA3.USD","LU0114720955.EUR","JGRO","IE000BZT7R73.USD","IE00B19Z3581.USD","LU0965508806.USD","LU0251142724.SGD","IE00BJJMRY28.SGD","LU0138981039.USD","LU2552382215.SGD","NVDB","FDTX","LU0210533765.USD","DCI","IE00BJJMRZ35.SGD","LU2931357623.SGD","LU1670711040.USD","LU0061474705.USD","PLYY","LU2720916845.USD","3NVD.UK","LU1670756490.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662791203","title":"Spyre股價下跌，因關節炎藥物未達研發目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2662791203","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662791203?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 17:29","pubTimestamp":1787736543,"startTime":"0","endTime":"0","summary":"BUZZ-Spyre股价下跌，因关节炎药物未达研发目标8月26日-** 药物研发公司Spyre Therapeutics（SYRE.O）的股价在盘前交易中下跌11.35%，报95.17美元** Spyre的试验性药物SPY072在中期临床试验中改善了类风湿性关节炎的症状(link)，但其疗效未达到将其开发为该病单药治疗方案的内部目标** 该研究针对中重度类风湿性关节炎患者（其病情对先前治疗反应不佳","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4T44N0LV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103784641","title":"Spyre Therapeutics盤前股價重挫12.4% 實驗性藥物未達類風濕關節炎單藥治療開發門檻","url":"https://stock-news.laohu8.com/highlight/detail?id=1103784641","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103784641?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 17:00","pubTimestamp":1787734809,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics股价在盘前交易时段大幅下跌12.4%，此前该公司宣布其一款实验性药物未能达到类风湿关节炎单药治疗开发所需的疗效阈值。这一消息令市场投资者颇感意外，引发对该生物科技公司研发管线前景的重新评估。受此利空冲击，该股在常规交易开始前即遭遇显著抛售压力，反映出市场对候选药物临床价值的疑虑正在加深。分析人士指出，未能跨越预设的疗效门槛意味着该药物作为单一疗法的开发路径将面临重大调整，公司或需重新考量其战略布局。投资者正密切关注公司后续的研发决策及可能的替代方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158063890","title":"Spyre Therapeutics公司——療效幅度未達公司預設目標，類風濕關節炎候選藥物SPY072單藥療法開發優先級或將調整","url":"https://stock-news.laohu8.com/highlight/detail?id=1158063890","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158063890?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 04:02","pubTimestamp":1787688131,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics公司近日披露，其类风湿关节炎在研药物SPY072在临床试验中展现的疗效幅度未能达到公司预先设定的目标阈值。这一结果意味着，该公司此前规划的单药疗法开发路径——即将SPY072作为独立治疗方案推进的优先策略——如今面临重新审视与调整的现实压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107207144","title":"Spyre Therapeutics公司：Spy072聯合Il17-a/F治療化膿性汗腺炎（HS）預計於2027年末或2028年初啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=1107207144","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107207144?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 04:02","pubTimestamp":1787688130,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc宣布，其候选药物Spy072与Il17-a/F联合疗法用于治疗化脓性汗腺炎（HS）的计划，预计将在2027年末或2028年初推进。这一时间表标志着该公司在炎症性疾病领域管线布局的重要节点，也反映出其对该联合方案临床开发节奏的审慎把控。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157101849","title":"Spyre Therapeutics——Spy072在多項終點指標上較安慰劑展現統計學顯著優勢","url":"https://stock-news.laohu8.com/highlight/detail?id=1157101849","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157101849?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 04:02","pubTimestamp":1787688129,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics宣布，其候选药物Spy072在多项临床试验终点上，相较于安慰剂组，取得了具有统计学意义的显著改善。这一积极结果标志着该药物在治疗潜力上迈出了坚实一步，为后续研发注入了强劲动力。尽管具体数据细节尚未完全披露，但公司方面对Spy072的前景表达了高度信心，并计划加速推进其临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103864507","title":"Spyre Therapeutics公布Spy072 Skyway二期試驗類風濕關節炎亞研究頂線結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1103864507","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103864507?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 04:02","pubTimestamp":1787688128,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics今日宣布，其Spy072在Skyway二期试验中针对类风湿关节炎亚研究的顶线结果已正式揭晓。这一里程碑式的数据发布，为该公司在自身免疫性疾病领域的研发管线注入了新的看点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661227372","title":"美國法院在DNA測序專利糾紛案中裁定Guardant公司支付2.45億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2661227372","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661227372?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:21","pubTimestamp":1787570491,"startTime":"0","endTime":"0","summary":"美国法院在DNA测序专利纠纷案中裁定Guardant公司支付2.45亿美元路透8月24日-TwinStrand Biosciences周一表示，美国一家法院裁定Guardant Health公司侵犯了涉及DNA测序技术的专利，并责令其向TwinStrand Biosciences和华盛顿大学支付超过2.452亿美元的赔偿金。法院裁定，Guardant必须就其11项被认定侵犯专利的产品及服务在美国的销售额，支付6%的专利使用费，直至2033年3月相关专利到期为止。TwinStrand表示，该判决所涵盖的产品和服务约占Guardant在侵权期间总收入的90%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL4T44L0SL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNOM","LU0109394709.USD","BK4196","GH","LFSC","GDOC","LU0320765992.SGD","GNMX","FFOX","PTH","BK4585","LU0889565916.HKD","EKG","BK4551","BK4535","HELX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160211496","title":"Twinstrand：法院判決公司及Uw獲賠逾2.452億美元，涵蓋截至2026年5月31日的侵權損害賠償、應計特許權使用費及利息","url":"https://stock-news.laohu8.com/highlight/detail?id=1160211496","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160211496?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:01","pubTimestamp":1787569302,"startTime":"0","endTime":"0","summary":"Twinstrand公告，法院已作出裁决，判令公司及Uw获得超过2.452亿美元的赔偿金。这笔款项涵盖了截至2026年5月31日期间所发生的侵权损害、累积的特许权使用费以及相应利息。\n裁决金额之巨，彰显了司法体系对知识产权保护的坚定立场。赔偿总额精确计算至该截止日期，包括了多层次的补偿要素。侵权行为的认定范围，则明确划定在2026年5月31日之前发生的全部相关行为。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","PTH","LU0109394709.USD","LFSC","EKG","HELX","BK4588","GH","GNOM","GNMX","LU0889565916.HKD","BK4196","BK4585","BK4551","FFOX","GDOC","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194764905","title":"Twinstrand勝訴：法院維持2023年故意侵權判決，並裁定Guardant Health 11項產品與服務須支付6%特許權使用費","url":"https://stock-news.laohu8.com/highlight/detail?id=1194764905","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194764905?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:01","pubTimestamp":1787569276,"startTime":"0","endTime":"0","summary":"法院裁定，维持2023年关于故意侵权的判决，同时要求Guardant Health公司就其11项产品及服务所产生的销售额，向Twinstrand支付6%的特许权使用费。这一裁决意味着，Twinstrand在知识产权纠纷中取得了关键性胜利。对于Guardant Health而言，这项决定无疑构成了财务上的重大负担。Twinstrand方面则对这一结果表示认可。此次6%特许权使用费的设定，亦反映了法院对此类行为的态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","GNMX","GDOC","GNOM","EKG","LFSC","FFOX","BK4551","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","PTH","BK4535","HELX","BK4196","GH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127912643","title":"Twinstrand案判決：Guardant Health須按季度向公司及承銷商彙報11款產品與服務的全美銷售明細","url":"https://stock-news.laohu8.com/highlight/detail?id=1127912643","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127912643?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569211,"startTime":"0","endTime":"0","summary":"根据Twinstrand方面的消息，法院判决要求Guardant Health必须履行一项新的义务——按季度提交其在美国市场上全部11款产品与服务的销售账目，以供公司与承销商查阅。\n这一判决意味着，Guardant Health在运营透明度和合规性上将面临更为严格的监督。具体而言，公司需定期整理并呈报相关销售数据，确保各方能够及时掌握其业务动态。\n此举无疑为市场参与者提供了更清晰的视角，去审视这家精准医疗领域领军企业的真实业绩表现。季度汇报机制的建立，或将进一步影响投资者对该公司未来走势的评估与判断。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","GH","EKG","LFSC","GDOC","BK4551","LU0320765992.SGD","GNOM","GNMX","FFOX","LU0109394709.USD","LU0889565916.HKD","PTH","BK4588","BK4196","HELX","BK4535"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":39,"code":"91000000","status":"200"}]}}